EDTXF
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.01 | $893,301 | -$2M |
| 2025 Q4 | -0.01 | $381,688 | -$3M |
| 2025 Q3 | -0.11 | $675,000 | -$3M |
| 2025 Q2 | -0.01 | $813,000 | -$3M |
| 2025 Q1 | -0.04 | $572,000 | -$1M |
| 2024 Q4 | 0.01 | $645,000 | -$2M |
| 2024 Q3 | -0.04 | $502,000 | -$3M |
| 2024 Q2 | -0.02 | $471,000 | -$2M |